IceCure Medical (ICCM)
Liquid-nitrogen cryoablation systems and disposable probes for minimally invasive tumor treatment.
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
Agreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the highest complete ablation rate among evaluated thermal ablation technologies CAESAREA, Israel, Aug. 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into an exclusive distribution agreement (the "Agreement") with Scovas Medical ("Scovas") for the distribution of IceCure's ProSense® cryoablation systems in the Netherlands for breast cancer and interventional oncology.
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN CAESAREA, Israel, Aug. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the Institutional Review Board (JHM-IRB) of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approval for the Company's post-marketing study ("ChoICE Study") for ProSense® cryoablation in the local treatment of low-risk breast cancer.
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second publication extends cryoablation's clinical role to axillary lymph node metastases CAESAREA, Israel, Aug. 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted two recent peer-reviewed publications by leading U.S. experts that reinforce the growing clinical role of cryoablation in breast cancer treatment de-escalation.
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash position CAESAREA, Israel, Aug. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial and operational results as of and for the six months ended June 30, 2026.
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval The site will be led by breast surgeon, Dr. Dennis Holmes, MD, FACS, a recognized leader in breast cancer cryoablation CAESAREA, Israel, August 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that Adventist Health Glendale in Glendale, California has signed an agreement and received approval from the Institutional Review Board to become the first clinical site able to enroll patients for the Company's post-marketing "ChoICE ," study (the "ChoICE Study"), for ProSense® in the local treatment of low-risk breast cancer following U.S Food and Drug Administration ("FDA") marketing authorization in October 2025.
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
CAESAREA, Israel, Aug. 5, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2026 before the Nasdaq Stock Market opens on Wednesday, August 12, 2026.
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
Company signed agreement with the West Cancer Center & Research Institute, the first clinical site for its post-marketing study for ProSense® cryoablation in the treatment of low-risk breast cancer CAESAREA, Israel, July 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the West Cancer Center & Research Institute in Germantown, Tennessee will serve as the first U.S. clinical site for the Company's post-marketing study "ChoICE," (the "ChoICE Study"), for ProSense® in the treatment of low-risk breast cancer following U.S Food and Drug Administration ("FDA") marketing authorization in October 2025.
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization Independent study evaluating breast cancer cryoablation in 750 patients across Brazil, led by renowned breast surgeon Dr. Vanessa Sanvido, is underway Dr. Toulsie Ramtohul of Institut Curie, a ProSense™ user set to lead a 900-patient breast cancer cryoablation study in France, invited to key Brazilian hospitals and interventional oncology conference to share clinical expertise CAESAREA, Israel, July 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted the growing international interest in its ProSense™ system in Brazil at the Simpósio de Radiologia Intervencionista em Oncologia ("SOBRICE Onco 2026"), one of the country's leading interventional oncology congresses.
IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
Published in the International Journal of Surgery, globally ranked in the top three among surgery journals , the article highlights strong clinical outcomes with ProSense® cryoablation and describes thermal ablation as a "beacon of hope for patients IceCure preparing for the 2026 Japanese Breast Cancer Society meeting and planned regulatory submission for breast cancer in Japan by Terumo Corporation one of the world's top 20 medical device companies CAESAREA, Israel, June 23, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlights a newly published peer-reviewed journal article presenting key clinical advantages of cryoablation over radiofrequency ablation ("RFA") for early-stage breast cancer, as the Company prepares to participate in the 34th Annual Meeting of the Japanese Breast Cancer Society ("JBCS"), taking place on June 25-27, 2026 in Kyoto, Japan.
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor
CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with a single healthcare focused institutional investor, for the purchase and sale of 1,833,334 ordinary shares (or ordinary share equivalents in lieu thereof), Series D Warrants to purchase up to 1,833,334 ordinary shares (the "Series D Warrants") and Series E Warrants to purchase up to 1,833,334 ordinary shares (the "Series E Warrants," and together with the Series D Warrants, the "Warrants") at a combined purchase price of $3.00 per share and accompanying Warrants in a private placement, priced at a premium to the previous Nasdaq closing price for the Company's ordinary shares.
IceCure Stock Surges After 70% ProSense Install Increase
IceCure Medical Ltd. (NASDAQ:ICCM) shares are soaring Wednesday after the company reported a 70% jump in its U.S. commercial install base for ProSense, its breast cancer cryoablation system.
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences compared to last year ProSense® breast cancer cryoablation procedures have been performed in major cities across the U.S. CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd.
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-free at a median follow-up of 4.0 years Independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes Independent study showed 92.9% reduction in fibroadenoma volume at 12 months post-treatment with ProSense® FDA clearance of ProSense® in early-stage breast cancer drives expanding global adoption and clinical interest in breast cryoablation CAESAREA, Israel, May 19, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that cryoablation and ProSense® were featured at the annual European Conference on Interventional Oncology ("ECIO") 2026, held in Basel, Switzerland on April 26 to 30, 2026.
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03.
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America
Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearance Accelerating adoption of ProSense® driven by several growth catalysts, including FDA clearance, expanding reimbursement framework, media coverage, growing body of clinical data and recommendation of cryoablation for breast cancer in leading clinical guidelines Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel, May 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2026 as well as recent commercial and clinical updates.
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
CAESAREA, Israel, May 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2026 before the Nasdaq Stock Market opens on Tuesday, May 12, 2026.
IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
As the only FDA cleared minimally invasive treatment option for low-risk breast cancer, ProSense® is aligned with the trend toward de-escalation of breast cancer treatment—a key theme at this year's meeting American Society of Breast Surgeons (ASBrS) recently recommend cryoablation for low-risk breast cancer in its updated Resource Guide IceCure sponsored a cryoablation symposium led by Key Opinion Leader breast physicians from leading medical institutions including Cleveland Clinic, University of Michigan, West Cancer Center, and the Warren Alpert Medical School of Brown University who shared their thoughts about and their experience using ProSense® Company expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in the first quarter of 2026 compared the same period last year, based on preliminary, unaudited estimates CAESAREA, Israel, May 5, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced its participation in the American Society of Breast Surgeons ("ASBrS") 2026 Annual Meeting, in Seattle from April 29 to May 3, 2026, where it exhibited ProSense® and sponsored a breakfast symposium titled "Unlocking De-Escalation: Cryoablation for Breast Cancer.
IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025
The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates Cryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract Award CAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd.